March 2023 - BioMedWire (BMW)

FridayMar 31, 2023 2:10 pm

Study Suggests Giving Babies Peanut Butter Cuts Allergy Risk

It seems that people are becoming more allergic to foods with every passing year. The West especially has seen a steady increase in the number of children who are allergic to different foods in recent decades, with 40% of American children now having some kind of food allergy. In the United Kingdom and Australia, 7% and 9% of children respectively have food allergies. Peanut allergies in the UK have increased by five times while Australia has the highest confirmed food allergy rate. Scientists believe that the key to reducing peanut allergy rates in children is to give four- to six-month-old…

FridayMar 31, 2023 9:00 am

Progressive Care Inc. (RXMD) Recent News Indicates Something Big Is Brewing

Restructuring whiz takes helm at RXMD New CEO takes no salary or other forms of compensation Company sees infusion of $6 million cash from key investors A synergistic tech-healthcare collaboration grows as financials show upward trend Looks like something big is brewing at Florida-based Progressive Care (OTCQB: RXMD). Focused on health services, the company offers healthcare services and technology that supports the managed healthcare industry to reduce costs and improve quality of care. The company has been steadily building both its pharmacy and data-management divisions as revenues continue to improve. However, a couple of extremely revealing events recently transpired that…

ThursdayMar 30, 2023 12:56 pm

AI Screens Brain Tumor Genes in Less Than Two Minutes

Brain tumors are among the deadliest medical conditions that affect humankind. More than 251,000 people succumbed to brain and central nervous system tumors in 2020, and an estimated 18,990 Americans are expected to lose their lives to brain and CNS tumors this year. Overall, brain and nervous system cancers are the 10th most prolific cause of death among adults. As such, it is crucial that physicians diagnose brain tumors as early as possible to ensure the means of treatment they use are as effective as possible. The past few years have seen medical researchers take advantage of artificial intelligence (AI)…

WednesdayMar 29, 2023 1:20 pm

Scientists Sound Alarm on Climate-Change-Induced Rise of Deadly infections

Climate change presents a significant risk to natural ecosystems and human societies worldwide. Several regions across the world are already experiencing weather disruptions such as flooding, droughts and extreme cold that are impacting human lives and established ecosystems in a myriad of ways. Experts in the United Kingdom believe that climate change may also result in an increase in the proliferation of potentially deadly infectious diseases caused by bacteria from America’s coastal region. As the climate continues to heat up from human industrial activity, the experts say that the number of infectious diseases along certain hot spots along the U.S.…

TuesdayMar 28, 2023 11:18 am

Research Links Smoking to Heightened Psoriasis Risk

A study published in the “Frontiers in Immunology” journal earlier this year has tied smoking to an increased risk of developing psoriasis. Psoriasis affects more than 8 million people in the United States and more than 125 million people globally, and the disease has no cure. It causes dry, itchy, raised, scaly-looking lesions on the skin that are discolored and can be quite sore. Triggers for the chronic condition include heavy alcohol consumption, smoking, skin injuries, infections, insect bites, cold temperatures and stress. Psoriasis is also associated with an increased risk of conditions such as diabetes, hypertension, obesity, dyslipidemia and…

TuesdayMar 28, 2023 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SP-26 as an alternative treatment for fibromyalgia The study, which is being carried out in conjunction with Experimur, has looked into the feasibility of using a time-released, dosage-controlled formulation of ketamine as a suitable treatment for the chronic medical condition Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced…

MondayMar 27, 2023 11:56 am

Debate Rages Regarding Patients Listing on Multiple Organ Transplant Wait Lists

Although thousands of people require organ transplants every year to address various conditions that cause organ failure, the supply of organs is not nearly enough to meet demand. As a result, people often spend years on waitlists, biding their time until they are lucky enough to receive a compatible organ before their health deteriorates to fatal levels. Thanks to a policy instituted in the late 1980s, patients can join wait lists for organ transplants in different treatment centers to increase their odds of finding a compatible organ faster. While this policy certainly gives patients a chance to increase their odds…

FridayMar 24, 2023 12:46 pm

Lighting Up Malignant Tissues Could Boost Precision of Surgical Removal

In most cases, the early discovery of cancer is directly tied to a patient’s chances of surviving the condition. Completely curing cancer may not be an option, but clinicians have several tools that allow them to kill off the majority of cancer cells and prevent them from spreading to healthy tissue. Surgery is usually considered when a tumor is present in only one part of the body and can be surgically removed in all its entirety. This approach to cancer treatment tends to be seen as “curative” because it seeks to completely remove cancer cells from the body. In many…

FridayMar 24, 2023 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain

CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”) This milestone is the culmination of years of meticulous planning and execution The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking…

ThursdayMar 23, 2023 12:41 pm

New Approach Could Boost Current Asthma Medication Efficacy

Asthma is a respiratory condition that affects 26.5 million Americans and around 300 million people worldwide. It is characterized by chronic inflammation in the lung airways that results in chest tightness, wheezing, shortness of breath or coughing. This tightening usually occurs when the involuntary muscles in the lung airways contract due to exposure to allergens, fumes, second-hand smoke or toxins. Treatment typically involves avoiding allergens and using remedies such as bronchodilators and anti-inflammatory agents. More specifically, drugs that can stimulate the β2-adrenergic receptors (β2AR) are instrumental in relaxing the lung airway muscles and promoting normal lung function. However, as with…